3 unchanged sentences
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
−Removed: JUNE 30, 2025 AND DECEMBER 31, 2024
+Added: SEPTEMBER 30, 2025 AND DECEMBER 31, 2024
(in thousands)
−Removed: JUNE 30, 2025
+Added: SEPTEMBER 30, 2025
DECEMBER 31, 2024
14 unchanged sentences
Deferred tax liability - Femcare IIA
−Removed: Other long term liabilities
Operating lease liability
4 unchanged sentences
authorized - 50,000 shares;
−Removed: issued and outstanding - June 30, 2025, 3,216 shares and December 31, 2024, 3,335 shares
−Removed: Accumulated other comprehensive loss
+Added: issued - September 30, 2025, 3,204 shares and December 31, 2024, 3,335 shares
+Added: Accumulated other comprehensive income (loss)
Additional paid-in capital
6 unchanged sentences
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
−Removed: THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND JUNE 30, 2024
+Added: THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024
(in thousands, except per share amounts - unaudited)
THREE MONTHS ENDED
−Removed: Six Months Ended
+Added: NINE MONTHS ENDED
+Added: SEPTEMBER 30,
+Added: SEPTEMBER 30,
Cost of goods sold
2 unchanged sentences
Research & development
−Removed: Total operating expenses
+Added: Total operating expense
Operating income
12 unchanged sentences
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
−Removed: FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND JUNE 30, 2024
+Added: FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND SEPTEMBER 30, 2024
(in thousands - unaudited)
−Removed: Six Months Ended
+Added: SEPTEMBER 30,
CASH FLOWS FROM OPERATING ACTIVITIES:
17 unchanged sentences
Intangible assets
−Removed: Proceeds from sale of property and equipment
+Added: Proceeds from sale of:
+Added: Property and equipment
Net cash used in investing activities
5 unchanged sentences
Effect of exchange rate changes on cash
−Removed: Net increase in cash and cash equivalents
+Added: Net increase/(decrease) in cash and cash equivalents
Cash at beginning of period
5 unchanged sentences
UTAH MEDICAL PRODUCTS, INC.
+Added: AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
−Removed: Three Months and Six Months Ended June 30, 2025 and 2024
+Added: Three and Nine Months Ended September 30, 2025 and 2024
(In thousands - unaudited)
1 unchanged sentence
Stockholders'
−Removed: Balance at December 31, 2024
+Added: Balance at June 30, 2025
Stock option compensation expense
2 unchanged sentences
Common stock dividends
−Removed: Balance at March 31, 2025
+Added: Balance at September 30, 2025
+Added: Balance at December 31, 2024
Stock option compensation expense
2 unchanged sentences
Common stock dividends
+Added: Balance at September 30, 2025
Balance at June 30, 2024
−Removed: Balance at December 31, 2023
Shares issued upon exercise of employee
4 unchanged sentences
Common stock dividends
−Removed: Balance at March 31, 2024
+Added: Balance at September 30, 2024
+Added: Balance at December 31, 2023
Shares issued upon exercise of employee
4 unchanged sentences
Common stock dividends
−Removed: Balance at June 30, 2024
+Added: Balance at September 30, 2024
see notes to consolidated condensed financial statements
UTAH MEDICAL PRODUCTS, INC.
+Added: AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
13 unchanged sentences
The Company is currently evaluating the impact of adopting ASU 2024-03.
−Removed: (3) Inventories at June 30, 2025 and December 31, 2024 consisted of the following:
+Added: (3) Inventories at September 30, 2025, and December 31, 2024, consisted of the following:
+Added: September 30,
Finished goods
2 unchanged sentences
(4) Stock-Based Compensation.
−Removed: At June 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.
+Added: At September 30, 2025, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.
The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation .
This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.
−Removed: In the quarters ended June 30, 2025 and 2024, the Company recognized $ 86 and $ 52 , respectively, in stock-based compensation expense.
−Removed: In the six months ended June 30, 2025 and 2024, the Company recognized $ 168 and $ 131 , respectively, in stock-based compensation expense.
+Added: In the quarters ended September 30, 2025, and 2024, the Company recognized $ 95 and $ 53 , respectively, in stock-based compensation cost.
+Added: In the nine months ended September 30, 2025, and 2024, the Company recognized $ 262 and $ 184 , respectively, in stock-based compensation cost.
(5) Warranty Reserve.
4 unchanged sentences
The amount of this reserve is adjusted, as required, to reflect its actual experience.
−Removed: Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024 or June 30, 2025.
+Added: Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2024, or September 30, 2025.
(6) Global 3Q 2025 revenues (USD) by product category:
+Added: Labor & Delivery
Gynecology/Electrosurgery/Urology
−Removed: Blood Pressure Monitoring and Accessories
−Removed: Global 1H 2025 revenues (USD) by product category:
+Added: Blood Pressure Monitoring and Accessorie s*
+Added: Global 9M 2025 revenues (USD) by product category:
+Added: Labor & Delivery
Gynecology/Electrosurgery/Urology
Blood Pressure Monitoring and Accessories*
+Added: *includes assemblies and molded components sold to OEM customers.
(7) Earnings Per Share.
Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period.
−Removed: Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2025.
+Added: Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3 rd quarter 2025.
The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:
1 unchanged sentence
Three months ended
−Removed: Six months ended
+Added: Nine months ended
+Added: September 30,
+Added: September 30,
Weighted average shares, basic
8 unchanged sentences
These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.
−Removed: The following table presents selected financial information with respect to the Company’s single operating segment for the quarters ended June 30, 2025 and June 30, 2024:
−Removed: Quarter Ended June 30,
+Added: The following table presents selected financial information with respect to the Company’s single operating segment for the quarters ended September 30, 2025 and September 30, 2024:
+Added: Quarter Ended September 30,
Standard cost of sales
13 unchanged sentences
UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.
−Removed: After June 30, 2025 through August 11, 2025, the Company made additional repurchases of 10,178 shares of its stock in the open market for $567, at an average price of $55.67 per share.
+Added: After September 30, 2025 through November 10, 2025, the Company made additional repurchases of 500 shares of its stock in the open market for $29, at a price of $57.90 per share.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.